STUDY ON INCENTIVES FOR DOMESTIC PRODUCTION OF GENERIC MEDICINES.

SEC. 2410. STUDY ON INCENTIVES FOR DOMESTIC PRODUCTION OF GENERIC MEDICINES.(a) In General.—The Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Assistant Secretary for Planning and Evaluation of the Department of Health and Human Services shall—(1) conduct a study on the feasibility, including related to sustainment, and potential effectiveness, and utility of providing incentives for increased domestic production and capacity of specified generic medicines and their active pharmaceutical ingredients, which may include through applicable nonprofit or for-profit private entities; and (2) not later than 1 year after the date of enactment of this Act, submit a report on such study to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives. (b) Specified Generic Medicine.—In this section, the term “specified generic medicine” means a generic drug approved under section 505(j) of the Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) that is —(1) used to prevent, mitigate, or treat a serious or life-threatening disease or condition, or used in a common procedure that could be life-threatening without such medicine; (2) an antibiotic or antifungal used to treat a serious or life threatening infectious disease; (3) critical to the public health during a public health emergency; or (4) life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition.